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We report a case of follicular B-cell lymphoma (FL) treated successfully using 
clarithromycin (CAM). A 44-year-old man who presented with lymphadenopathy was 
diagnosed with FL after a histological examination of his biopsy specimens. He was 
administered chemotherapy with R-CHOP (rituximab, cyclophosphamide, adriamycin, 
vincristine, and prednisolone) following which stable disease was achieved. However, 
the subsequent clinical course showed partial remission of FL and stable disease with 
tumor regrowth, each of which was treated with chemotherapeutic regimens. Since the 
patient was diagnosed with leukocytopenia, he could not undergo chemotherapy for the 
third regrowth; hence, he was administered CAM. His lymphadenopathy regressed and 
the levels of soluble interleukin 2-receptor decreased. This case shows that treatment 
using CAM may be effective in some cases of FL.
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INTRODUCTION
Antibiotics are considered promising candidates for 
anticancer drugs because of their good tolerability and direct 
pro-apoptotic effects on tumor cells [1]. Macrolides, among 
the other antibiotics, have been thought to be potential 
antineoplastic and immunomodulatory agents [1]. As anti-
neoplastic agents, macrolides show antilymphoproliferative 
effects through the down-regulation of the bcl-2 and bcl-xL 
proteins, both of which prevent apoptosis [2, 3]. Many cases 
of cancer, such as, mucosa-associated lymphoid tissue (MALT) 
lymphoma [1, 4], macroglobulinemia, multiple myeloma [5], 
relapse of Hodgkin’s lymphoma [6], and follicular lymphoma 
[7] have been treated successfully using macrolides. We 
present a patient with stage IV follicular B-cell lymphoma 
(FL) who was treated successfully using clarithromycin 
(CAM).
CASE REPORT
A 44-year-old man with bilateral cervical lymphade-
nopathy was admitted to the hospital. He had no history 
of fever, general fatigue, or weight loss. Physical examination 
showed several swollen lymph nodes in the right and left 
cervical, left axillary, and left inguinal regions. The patient’s 
LDH levels and serum levels of soluble interleukin 2 receptor 
(sIL2-R) had increased to 293 IU/L and 1,911 U/mL, 
respectively. Computed tomography (CT) revealed cervical, 
axillary, inguinal, and para-aortic lymphadenopathy (Fig. 
1A). Esophagogastroduodenoscopy (EGD) and colonoscopy 
(CS) showed no abnormal lesions associated with lymphoma. 
The biopsy specimens of the cervical lymph nodes showed 
well-circumscribed  follicles composed of a monotonous 
population of predominantly small-cleaved cells that were 
positive for CD10 and CD20 but negative for CD5 and cyclin 
D1 (Fig. 2A). In the immunohistochemical study for the 
presence of bcl-2 protein, the small-cleaved cells stained 
positive (Fig. 2B). These atypical cells were detected in the 
bone marrow aspirates as well. Chromosome analysis of the 
cervical lymph node cells showed t(14;18)(q32;q21) translo-
cation. On the basis of all these results, the patient was 
diagnosed with stage IV FL, and was classified as a high-risk 
patient since his follicular lymphoma international pro-
gnostic index (FLIPI) score was 3 points. The clinical course 
of the disease is shown in Fig. 3. Stable disease was achieved 
in the patient after 6 cycles of chemotherapy with R-CHOP 
(rituximab, cyclophosphamide, adriamycin, vincristine, and 
prednisolone), and the patient was discharged. Korean J Hematol 2011;46:203-6.
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Fig. 1. Computed tomography. (A) Contrast-enhanced abdominal computed tomography (CT) image showing para-aortic lymphadenopathy at the
time of admission. (B) Abdominal CT image showing para-aortic lymphadenopathy after completion of 6 cycles of R-CHOP chemotherapy 
(rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone). (C) Abdominal CT image showing para-aortic lymphadenopathy (first
regrowth). (D) Abdominal CT image showing para-aortic lymphadenopathy after completion of 5 cycles of R-cladribine therapy. (E) Abdominal CT
image showing para-aortic lymphadenopathy just before the first R-monotherapy. (F) Abdominal CT image showing para-aortic lymphadenopathy
5 months after completion of 4 cycles of R-monotherapy. (G) Abdominal CT showing para-aortic lymphadenopathy (second regrowth). (H)
Abdominal CT image showing para-aortic lymphadenopathy after completion of 5 cycles of R-fludarabine therapy. (I) Abdominal CT image showing
para-aortic lymphadenopathy (third regrowth). (J) Abdominal CT image showing par-aortic lymphadenopathy 3 months after initiation of 
clarithromycin (800 mg/day) treatment. (K) Abdominal CT image showing para-aortic lymphadenopathy 9 months after initiation of clarithromycin
(800 mg/day) treatment.
About 2 years later, cervical and para-aortic lympha-
denopathy aggravated (Fig. 1C), and the levels of sIL2-R 
increased to 748 U/mL (first tumor regrowth). He was treated 
with 5 cycles of chemotherapy with R-cladribine followed 
by 4 cycles of rituximab monotherapy 2 times every 6 months. 
In the course of these chemotherapies, the para-aortic 
lymphadenopathy and sIL2-R levels improved (Fig. 1D-F). 
However, 5 months after these chemotherapies, the patient’s 
condition deteriorated again, with an aggravation of the 
para-aortic lymphadenopathy and increase in sIL2-R levels 
(second tumor regrowth) (Fig. 1G). The patient was treated 
with 5 cycles of R-fludarabine chemotherapy, in the course Korean J Hematol 2011;46:203-6.
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Fig. 2. Histological and immunohistochemical examination of cervical 
lymph node biopsy specimens. (A) Histological examination showing 
well-circumscribed follicles consisting of a monotonous population of 
predominantly small-cleaved cells (Hematoxylin and eosin stain, ×100).
(B) Immunohistochemical examination for bcl-2 showing positive 
staining in the small-cleaved cells (Immunohistochemical stain, ×400).
Fig. 3. Clinical course. sIL2-R, soluble interleukin 2 receptor; R, 
rituximab;  C,  cyclophosphamide; H, adriamycin;  O, vincristine; P, 
prednisolone;  CAM,  clarithromycin.
of which, the para-aortic lymphadenopathy improved 
slightly (Fig. 1H) and sIL2-R levels decreased from 406 to 
183 U/mL. About 1 year after the second regrowth, 
para-aortic lymphadenopathy worsened and his sIL2-R levels 
elevated (478 U/mL) (third tumor regrowth) (Fig. 1I). Since 
the patient had prolonged leukocytopenia (number of 
leukocytes=1,500-1,800/mm
3) resulting from chemotherapy, 
he was administered CAM (400 mg/day), which is known 
to induce apoptosis in B-cell lymphoma, instead of conven-
tional chemotherapy after obtaining informed consent. Two 
months after the administration of CAM, only a slight 
increase was observed in his IL2-R levels (478-480 U/mL). 
However, the levels ultimately increased to 537 U/mL, and 
hence, the dosage of CAM was doubled (800 mg/day). CT 
images obtained 3 months later showed improvement of 
para-aortic lymphadenopathy (Fig. 1J). The levels of sIL2-R 
also decreased from 537 to 268 U/mL by 6 weeks after the 
dosage was increased. CT images obtained 9 months after 
the initiation of the CAM therapy at 800 mg/day showed 
that the para-aortic lymphadenopathy improved further, 
albeit slightly (Fig. 1K), and that the sIL2-R level was constant 
at 200 U/mL. Mild diarrhea was noted as a side effect of 
the long-term use of CAM.
DISCUSSION
A newly proposed prognostic index for FL-FLIPI-classifies 
the prognosis of FL into 3 groups [8]. On the basis of the 
FLIPI score, our patient was classified as being a high-risk 
patient. Since the patient had no organ dysfunction, 
cytopenia, or bulky disease, watchful waiting could have 
been an option, but the patient chose to undergo chemo-
therapy. The risk of histological transformation is higher 
in patients who have advanced-stage disease and have been 
determined to be at high-risk on the basis of the FLIPI 
score at diagnosis [9]; hence, we decided to continue the 
treatment. 
Macrolides are thought to be potential antineoplastic and 
immunomodulatory agents [1]. CAM, a macrolide antibiotic, 
is known to induce apoptosis in B-cell lymphoma cells [10]. 
After the third tumor regrowth, the patient was administered 
CAM instead of conventional chemotherapy. CAM when 
administered at a dosage of 400 mg/day, appeared to be 
slightly effective, since it arrested the rapid elevation of 
sIL2-R levels. However, when administered at a dosage of 
800 mg/day, CAM appeared to be very effective because 
it rapidly decreased the levels of sIL2-R and improved the 
lymphadenopathy. Thus, CAM at a dose of 800 mg/day can 
be concluded to have antilymphoproliferative effects.
Macrolides, such as CAM and rapamycin, have anti- 
proliferative activities against a variety of B-cell proliferative 
diseases [1, 2, 4-6]. Ishimatsu et al. [4] reported 2 cases 
of pulmonary MALT lymphoma successfully treated with 
low-dose, long-term CAM therapy (200 mg/day); they specu-
lated that the macrolide induces apoptosis in lymphocytes 
via the down-regulation of bcl-xL protein expression. 
Similarly, Hayun et al. [2] reported that rapamycin and 
curcumin induces apoptosis in resting cells in B-cell chronic 
lymphocytic leukemia (B-CLL); they found that rapamycin 
decreases the levels of the anti-apoptotic protein bcl-2 and 
increases the levels of the pro-apoptotic protein Bax. These 
results show a clear transition from an anti-apoptotic to 
a pro-apoptotic signal in the tumor cells. 
In our case, chromosome analysis identified t(14;18) 
(q32;q21) translocation-a frequent chromosomal aberration 
in FL, involving the immunoglobulin heavy chain (IgH) gene 
on chromosome 14q32 and the bcl-2 gene on chromosome 
18q12. This translocation results in up-regulation of bcl-2 
protein expression in most cases of FL [11]. The bcl-2 protein Korean J Hematol 2011;46:203-6.
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inhibits apoptosis, thus leading to immortality of the cells. 
Similarly, the bcl-xL gene, which exerts an anti-apoptotic 
effect on lymphocytes, is over-expressed in FL patients [12].
The lymphoma cells from our patient stained positive for 
bcl-2 in the immunohistochemical examination. Therefore, 
the mechanism by which macrolides inhibit lympho-
proliferative disorders may be through their effects on bcl-2 
and probably bcl-xL.
Although MALT lymphoma could be controlled with only 
200 mg/day of CAM, a dose of 800 mg/day was required 
to control FL in our patient. This suggests that lymphoproli-
f erat iv e activity in FL is h igh er t h an  th at in MA LT  lympho ma. 
Yaguchi et al. [7] also reported partial regression of 
duodenal lesions in intestinal FL after antibiotic treatment. 
According to their report, the patient was treated with 
lansoprazole (30 mg twice daily), CAM (400 mg twice daily), 
and amoxicillin (750 mg twice daily) for 7 days, although 
the tests for Helicobacter pylori were negative. EGD per-
formed after 3 months confirmed the regression of duodenal 
lesions. Because antibiotic treatment induced regression, 
they speculated that antigenic stimuli from a source other 
than  H. pylori might play a role in the pathogenesis of 
this lymphoma.
In our patient, no abnormal lesions associated with lym-
phoma were observed after performing EGD and CS at the 
time of admission. Additionally, the results of the anti-H. 
pylori immunoglobulin (Ig) antibody test was negative. We 
therefore concluded that, our patient’s condition was not 
associated with H. pylori infection. The effectiveness of CAM 
treatment indicates that CAM may have antilympho-
proliferative activity, and not just antibiotic activity.
More extensive research is required to substantiate our 
findings and determine the optimal dose, estimate the res-
ponse rate, and assess the effectiveness of our CAM regimen 
alone or in combination with other agents.
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